Arguably, mTORC1 activation has been shown to contribute to NF-κB signalling, so standard therapy with mTORC1 inhibitors in TSC patients should have some capacity to prevent the inappropriate activity of NF-κB [44]. Here, NFKB1 is linked to tuberous sclerosis.